319 related articles for article (PubMed ID: 23890782)
1. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
Muñoz Torres M
Endocrinol Nutr; 2014 Mar; 61(3):153-9. PubMed ID: 23890782
[TBL] [Abstract][Full Text] [Related]
2. Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
Berard L; MacNeill G
Can J Diabetes; 2015 Feb; 39(1):4-9. PubMed ID: 25065475
[TBL] [Abstract][Full Text] [Related]
3. Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
Owens DR; Matfin G; Monnier L
Diabetes Metab Res Rev; 2014 Feb; 30(2):104-19. PubMed ID: 24026961
[TBL] [Abstract][Full Text] [Related]
4. Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.
Kerlan V; Gouet D; Marre M; Renard É
Ann Endocrinol (Paris); 2013 Dec; 74(5-6):487-90. PubMed ID: 23978337
[TBL] [Abstract][Full Text] [Related]
5. Treating to target in type 2 diabetes: the BEGIN trial programme.
Wangnoo SK; Chowdhury S; Rao PV
J Assoc Physicians India; 2014 Jan; 62(1 Suppl):21-6. PubMed ID: 25330628
[TBL] [Abstract][Full Text] [Related]
6. Insulin degludec. Uncertainty over cardiovascular harms.
Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
[TBL] [Abstract][Full Text] [Related]
7. A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus.
Woo VC
Clin Ther; 2017 Aug; 39(8S2):S12-S33. PubMed ID: 28187863
[TBL] [Abstract][Full Text] [Related]
8. Insulin degludec: a novel basal insulin analogue.
Goldman-Levine JD; Patel DK; Schnee DM
Ann Pharmacother; 2013 Feb; 47(2):269-77. PubMed ID: 23386075
[TBL] [Abstract][Full Text] [Related]
9. [New insulin types in type 1 diabetes mellitus].
Mesa J
Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
11. Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec.
Robinson JD; Neumiller JJ; Campbell RK
Drugs; 2012 Dec; 72(18):2319-25. PubMed ID: 23145524
[TBL] [Abstract][Full Text] [Related]
12. Understanding the safety of the new ultra long acting basal insulin.
Ramachandran A; Gupta V; Kesavadev J; Kalra S
J Assoc Physicians India; 2014 Jan; 62(1 Suppl):35-42. PubMed ID: 25330630
[TBL] [Abstract][Full Text] [Related]
13. [Diabetes mellitus type 1 and 2. Flexible therapy with insulin degludec].
Rausch R
Med Monatsschr Pharm; 2014 Jul; 37(7):273-4. PubMed ID: 25065174
[No Abstract] [Full Text] [Related]
14. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
Pollock RF; Tikkanen CK
J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
[TBL] [Abstract][Full Text] [Related]
15. Switching "Real-World" Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control.
Tentolouris N; Knudsen ST; Lapolla A; Wolden ML; Haldrup S; Schultes B
Adv Ther; 2019 May; 36(5):1201-1210. PubMed ID: 30879256
[TBL] [Abstract][Full Text] [Related]
16. Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.
Gallegos Aragon K; Elmaoued AA; Pham NT; Conklin JR; Ray GM
Cardiol Rev; 2019; 27(5):260-266. PubMed ID: 31393288
[TBL] [Abstract][Full Text] [Related]
17. Degludec: a novel basal insulin.
Kalra S; Baruah MP; Niazi AK
Recent Pat Endocr Metab Immune Drug Discov; 2012 Jan; 6(1):18-23. PubMed ID: 22280221
[TBL] [Abstract][Full Text] [Related]
18. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
[TBL] [Abstract][Full Text] [Related]
19. Hypoglycemia rates with basal insulin analogs.
Little S; Shaw J; Home P
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
[TBL] [Abstract][Full Text] [Related]
20. Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials.
Preumont V; Buysschaert M
Diabetes Metab; 2020 Apr; 46(2):83-88. PubMed ID: 31055056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
